Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) Overview | 6 | 1 |
| Therapeutics Development | 7 | 3 |
| Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) Products under Development by Stage of Development | 7 | 1 |
| Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) Products under Development by Therapy Area | 8 | 1 |
| Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) Products under Development by Indication | 9 | 1 |
| Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) Pipeline Products Glance | 10 | 2 |
| Late Stage Products | 10 | 1 |
| Early Stage Products | 11 | 1 |
| Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) Products under Development by Companies | 12 | 2 |
| Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) Therapeutics Assessment | 14 | 4 |
| Assessment by Monotherapy/Combination Products | 14 | 1 |
| Assessment by Mechanism of Action | 15 | 1 |
| Assessment by Route of Administration | 16 | 1 |
| Assessment by Molecule Type | 17 | 1 |
| Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) Companies Involved in Therapeutics Development | 18 | 4 |
| AbbVie Inc | 18 | 1 |
| OncoMed Pharmaceuticals, Inc. | 19 | 1 |
| PharmAbcine, Inc. | 20 | 1 |
| Sevion Therapeutics, Inc. | 21 | 1 |
| Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) Drug Profiles | 22 | 14 |
| ABT-165 Drug Profile | 22 | 1 |
| demcizumab Drug Profile | 23 | 8 |
| Monoclonal Antibody to Inhibit DLL4 for Oncology Drug Profile | 31 | 1 |
| Monoclonal Antibody to Inhibit DLL4 for Oncology and Inflammatory Disorders Drug Profile | 32 | 1 |
| OMP-305B83 Drug Profile | 33 | 2 |
| PMC-201 Drug Profile | 35 | 1 |
| Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) Dormant Projects | 36 | 1 |
| Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) Discontinued Products | 37 | 1 |
| Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) Featured News &Press Releases | 38 | 12 |
| Sep 01, 2016: OncoMed Pharmaceuticals Completes Enrollment of Phase 2 YOSEMITE Clinical Trial of Demcizumab in Pancreatic Cancer | 38 | 1 |
| Jun 05, 2016: OncoMed Presents Phase 1b Data on demcizumab at the 2016 ASCO Annual Meeting | 38 | 1 |
| May 18, 2016: AbbVie To Present Data on ABT-165 at ASCO 2016 | 39 | 1 |
| Apr 21, 2016: OncoMed Announces Clinical Data for Demcizumab to be Presented at the 2016 ASCO Annual Meeting | 40 | 1 |
| Apr 20, 2016: OncoMed Presents Demcizumab Mechanism Data at the AACR Annual Meeting 2016 | 40 | 1 |
| Mar 17, 2016: OncoMed Initiates Phase 1b Immuno-Oncology Combination Clinical Trial for Demcizumab and Pembrolizumab (anti-PD1) | 41 | 1 |
| Jan 22, 2016: OncoMed Presents Updated Phase 1b Data for Demcizumab in First-Line Pancreatic Cancer at the Gastrointestinal Cancers Symposium | 42 | 1 |
| Nov 09, 2015: OncoMed Presents Data From Anti-DLL4/VEGF Bispecific Program at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics | 43 | 1 |
| Nov 07, 2015: OncoMed Presents Immuno-Oncology Data for Combined Blockade of DLL4, VEGF and PD1 at the Society for Immunotherapy of Cancer Annual Meeting | 44 | 1 |
| Nov 04, 2015: OncoMed to Present Preclinical Data for the Combination of anti-DLL4/VEGF Bispecific plus anti-PD1 at the Society of Immunotherapy for Cancer Meeting | 44 | 1 |
| Oct 27, 2015: OncoMed to present preclinical results from OMP-305B83 at the AACR-NCI-EORTC International Conference | 45 | 1 |
| Aug 10, 2015: OncoMed Pharmaceuticals Updates Demcizumab Phase 1b Non-Small Cell Lung Cancer Survival Data | 45 | 2 |
| Jun 01, 2015: OncoMed Presents Data From Phase 1b Trial of Demcizumab in Pancreatic Cancer at the 2015 ASCO Annual Meeting | 47 | 1 |
| Jun 01, 2015: OncoMed Presents Updated Demcizumab Data in Non-Small Cell Lung Cancer at the 2015 ASCO Annual Meeting | 48 | 1 |
| May 28, 2015: OncoMed Pharmaceuticals to Review Key ASCO Data for Demcizumab During Conference Call on Tuesday, June 2, 2015 | 49 | 1 |
| Appendix | 50 | 2 |
| Methodology | 50 | 1 |
| Coverage | 50 | 1 |
| Secondary Research | 50 | 1 |
| Primary Research | 50 | 1 |
| Expert Panel Validation | 50 | 1 |
| Contact Us | 50 | 1 |
| Disclaimer | 51 | 1 |